PDCNeo+

The PDC*neo+ project aims to develop PDC*neo+, a personalised therapeutic vaccine for colorectal cancer (CRC), using PDC*LINE PHARMA’s innovative PDC*line technology. Targeting unique neoantigens in each CRC patient, PDC*neo+ represents a groundbreaking approach in cancer immunotherapy.

CRC is among the most prevalent and deadly cancers globally, with a high recurrence rate post-surgery and chemotherapy. PDC*neo+ is designed as an adjuvant treatment to prevent relapses in high-risk patients with stages II, III, and certain stage IV CRC. This aligns with chemotherapy, potentially making it a pioneering treatment in CRC.

This project is a collaborative effort involving several key partners. OncoDNA contributes with its expertise in personalised medicine, focusing on neoantigen identification and circulating tumour DNA analysis. salamanderU is developing a compact isolator for decentralised vaccine production. Academic centers UCLouvain – IREC/MIRO and ULB-BCTL offer vital support in translational research and clinical trial execution.

The main goal is to confirm the clinical feasibility and safety of PDC*neo+ in a Phase I trial. This initiative is expected to have a significant impact on CRC patient care, alongside broader economic and societal benefits. The project is estimated to create or maintain around 34 full-time jobs across all partners.